Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
Clin Lymphoma Myeloma Leuk
; 17(5): 252-262, 2017 05.
Article
em En
| MEDLINE
| ID: mdl-28366781
ABSTRACT
Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Macroglobulinemia de Waldenstrom
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Lymphoma Myeloma Leuk
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2017
Tipo de documento:
Article